Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398103 | 0.85 | THRB (0.54) | ALDH1A1KMT2ANPC1THRBATM | |
| SCHEMBL6398113 | 0.85 | THRB (0.54) | ALDH1A1KMT2ANPC1THRBATM | |
| SCHEMBL7198122 | 0.82 | ALDH1A1 (0.53) | ALDH1A1PTGDRKMT2AKDM4ENPC1 | |
| SCHEMBL1207346 | 0.74 | THRB (0.66) | KMT2AKDM4EGCKNPC1THRB | |
| SCHEMBL1207345 | 0.74 | THRB (0.66) | KMT2AKDM4EGCKNPC1THRB | |
| SCHEMBL7797914 | 0.74 | TDO2 (0.54) | ALDH1A1KDM4ESMN1; SMN2MIF | |
| SCHEMBL1950982 | 0.74 | TDO2 (0.54) | ALDH1A1KDM4ESMN1; SMN2MIF | |
| SCHEMBL926135 | 0.74 | AKR1C3 (0.54) | ALDH1A1KMT2AKDM4EGCKTHRB | |
| SCHEMBL926134 | 0.74 | AKR1C3 (0.54) | ALDH1A1KMT2AKDM4EGCKTHRB | |
| SCHEMBL11364258 | 0.74 | MAPT (0.67) | ALDH1A1KMT2ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1965915-B1 | SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS | RAPP POLYMERE GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-20110009621-A1 | SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS | Raap Polymere GmbH (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-1965915-A1 | SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS | Rapp Polymere GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007065907-A1 | SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS | RAPP POLYMERE GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009621-A1 | SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS | SCO2, SOD1, PPIF | ALDH1A1 1241/4885PTGDR 3094/4885KMT2A 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.